STOCK TITAN

Structure Therapeutics: Deep Track reports 7.18% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

For Structure Therapeutics Inc. (GPCR), Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively report beneficial ownership of 15,000,000 ordinary shares, equal to 7.18% of the class as of September 30, 2026. Each reporting person's cover page lists shared voting and dispositive power over 15,000,000 shares and zero sole voting or dispositive power.

Beneficial ownership 15,000,000 ordinary shares Reported collectively as of September 30, 2026
Ownership percentage 7.18% Percentage of the class as of September 30, 2026
Shares outstanding 208,862,772 common shares As of July 31, 2026; cited as the basis for the ownership percentage
American Depositary Shares 5,000,000 ADSs Each ADS represents, and at the holder's option is convertible into, three ordinary shares
beneficially owned regulatory
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared Voting Power regulatory
"Shared Voting Power 15,000,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Power regulatory
"Shared Dispositive Power 15,000,000.00"
American Depositary Shares technical
"5,000,000 American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GPCR shares do the reporting persons beneficially own?

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin report beneficial ownership of 15,000,000 ordinary shares, or 7.18% of the class, as of September 30, 2026. Each reporting person's cover page lists shared voting and dispositive power over 15,000,000 shares.

How many ADSs are represented in the GPCR ownership report?

The 15,000,000 ordinary shares consist of 5,000,000 American Depositary Shares; each ADS represents, and at the holder's option is convertible into, three ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





86366E106

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Deep Track Capital, LP
Signature:David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:11/16/2026
Deep Track Biotechnology Master Fund, Ltd.
Signature:David Kroin
Name/Title:David Kroin, Director
Date:11/16/2026
David Kroin
Signature:David Kroin
Name/Title:David Kroin
Date:11/16/2026
Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Shares as of September 30, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 208,862,772 Common Shares outstanding as of July 31, 2026, according to the issuer's 10-Q filed with the SEC on August 6, 2026. Deep Track Capital LP, Deep Track Biotechnology Master Fund Ltd and David Kroin, together as the Reporting Persons', beneficially owns an aggregate of 15,000,000 ordinary shares of Structure Therapeutics Inc., consisting of 5,000,000 American Depositary Shares, each of which represents, and at the holder's option is convertible into, three ordinary shares JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

Keep reading